COVID-19 vaccine Archives | Page 14 of 19 | Be Korea-savvy
Sabin Vaccine Institute Funds Researchers to Investigate COVID-19 Misinformation, Design Solutions to Increase Vaccine Acceptance

Sabin Vaccine Institute Funds Researchers to Investigate COVID-19 Misinformation, Design Solutions to Increase Vaccine Acceptance

WASHINGTON, Jan. 13 (Korea Bizwire) — The Sabin Vaccine Institute (Sabin) announced today that it has awarded grants to research teams in four countries to explore the social drivers of COVID-19 misinformation, and its impact on routine immunization acceptance and the acceptance of a COVID-19 vaccine. The grants are part of Sabin’s Social and Behavioral [...]

Novavax Finalizes Agreement with Commonwealth of Australia for 51 Million Doses of COVID-19 Vaccine

Novavax Finalizes Agreement with Commonwealth of Australia for 51 Million Doses of COVID-19 Vaccine

GAITHERSBURG, Md., Jan. 7 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has executed an Advance Purchase Agreement with the Commonwealth of Australia for 51 million doses of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. This follows an agreement in principle that was [...]

S. Korea Decides to Allow Troops, Citizens Working for USFK to Get COVID-19 Vaccinations

S. Korea Decides to Allow Troops, Citizens Working for USFK to Get COVID-19 Vaccinations

SEOUL, Dec. 30 (Korea Bizwire) — The defense ministry decided Wednesday to allow South Korean soldiers and civilian workers affiliated with the U.S. Forces Korea (USFK) to get COVID-19 vaccinations shipped from the U.S. for its troops stationed here, officials said. The South Korean troops affiliated with the Korean Augmentation to the U.S. Army, known [...]

Novavax Announces Initiation of PREVENT-19 Pivotal Phase 3 Efficacy Trial of COVID-19 Vaccine in the United States and Mexico

Novavax Announces Initiation of PREVENT-19 Pivotal Phase 3 Efficacy Trial of COVID-19 Vaccine in the United States and Mexico

GAITHERSBURG, Md., Dec. 28 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced initiation of PREVENT-19, its pivotal Phase 3 study in the United States and Mexico to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373, the Company’s COVID-19 vaccine candidate. The trial builds [...]